Zhongshan Akeso Biopharma Inc ( Akeso Biopharma) has passed the listing hearing a few days ago by HKEX (Hong Kong Exchanges and Clearing Limited) and offered shares from April 14 to 17, raising about 200-300 million US dollars, with a share price of 14.88-16.18 Hong Kong dollars. It is expected to be listed on April 24.

Akeso Biopharma, founded in March 2012 by a team of 4 overseas returnees with doctoral degrees, is an innovative bio-pharmaceutical company headquartered in Zhongshan's National Health Technology Park. The company is committed to independently discovering, developing, and commercializing new drugs and similar antibody biological drugs, aiming to solve major medical needs worldwide in tumor, immunization, and other therapeutic fields.

In addition to listing, Akeso Biopharma will accelerate the construction of a commercial production base for bio-drugs based on international GMP standards, starting with the construction of Akeso Biopharma Bay Area Industrial Park and planning to build Akeso Biopharma Bay Area Science Park in Tsuihang New District.